Clinical Trial Update: Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial [NA]

View source ↗

Summary

A double-blind randomized trial comparing rifaximin plus lactulose versus lactulose alone for hepatic encephalopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy

Drugs mentioned

• LACTULOSE (Lactulose)
• Rifaximin (Xifaxan) (rifaximin)

Snippet

Sponsor: Institute of Liver and Biliary Sciences, India | Conditions: Hepatic Encephalopathy | NA | Status: COMPLETED